CD19 and neoplasm: In 2013, Themeli et al. utilized CD19 CAR-T-PSCs (T cell-derived PSCs expressing CD19 CAR construct) to generate cytotoxic lymphocyte, initiating tumor regression in Raji Burkitt lymphoma mouse model [45].